These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 26383821

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, Yang M, Zhang Y, Xiong D.
    J Hematol Oncol; 2015 Feb 28; 8():18. PubMed ID: 25879549
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U.
    Cancer Immunol Immunother; 2008 Jan 28; 57(1):43-52. PubMed ID: 17579857
    [Abstract] [Full Text] [Related]

  • 12. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, Slootstra JW, Baeuerle PA, Kufer P, Rattel B.
    Mol Cancer Ther; 2014 Jun 28; 13(6):1549-57. PubMed ID: 24674885
    [Abstract] [Full Text] [Related]

  • 13. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
    Zhang X, Yang Y, Zhang L, Lu Y, Zhang Q, Fan D, Zhang Y, Zhang Y, Ye Z, Xiong D.
    J Hematol Oncol; 2017 Feb 23; 10(1):56. PubMed ID: 28228105
    [Abstract] [Full Text] [Related]

  • 14. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
    Reusing SB, Vallera DA, Manser AR, Vatrin T, Bhatia S, Felices M, Miller JS, Uhrberg M, Babor F.
    Cancer Immunol Immunother; 2021 Dec 23; 70(12):3701-3708. PubMed ID: 34398302
    [Abstract] [Full Text] [Related]

  • 15. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.
    Hoseini SS, Guo H, Wu Z, Hatano MN, Cheung NV.
    Blood Adv; 2018 Jun 12; 2(11):1250-1258. PubMed ID: 29858209
    [Abstract] [Full Text] [Related]

  • 16. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
    O'Hear C, Heiber JF, Schubert I, Fey G, Geiger TL.
    Haematologica; 2015 Mar 12; 100(3):336-44. PubMed ID: 25480499
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R, Saul D, Braun M, Tohumeken S, Völkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D.
    J Immunother Cancer; 2018 Nov 05; 6(1):116. PubMed ID: 30396365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.